Exhale

The official blog of the Lung Institute.

What is Pneumoconiosis?

What is Pneumoconiosis?

Pneumoconiosis is a term that can refer to any chronic lung condition caused by the inhalation of dust or toxic fibers. Silicosis (caused by the inhalation of silica dust), asbestosis (caused by the inhalation of asbestos) and black lung disease (caused by the inhalation of coal or graphite dust) are all forms of pneumoconiosis, which is characterized by severe scarring and inflammation in the lungs.

Pneumoconiosis can cause a number of uncomfortable symptoms, including:

  • Chest pain
  • Shortness of breath, both at rest and during physical activity
  • A persistent cough
  • Low blood oxygen levels (hypoxemia)

People with pneumoconiosis can use medications and supplemental oxygen treatment to help alleviate these symptoms, although there is no way to reverse existing lung damage or cure the condition in its entirety. Some people, however, have turned to alternative therapies to help slow the progression of the disease. cellular therapy is one such option that may help alleviate inflammation and promote the body’s natural healing process. An innovative treatment option, cellular therapy does not typically cause any side effects and can be provided alongside other traditional forms of pneumoconiosis treatment.

The Lung Institute – the world’s only cellular therapy center to focus exclusively on the treatment of lung disease – offers cellular therapy for pneumoconiosis. We have helped numerous patients manage their pneumoconiosis symptoms and improve their quality of life – even when traditional treatments have failed to produce the desired results.

If you or a loved one has been diagnosed with pneumoconiosis and would like to learn more about your treatment options, contact the Lung Institute by calling (800) 729-3065 to speak with a caring member of our team. We can help you determine if our cellular therapys may be an optimal pneumoconiosis treatment for you.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.